Shares of C4 Therapeutics CCCC, or C4T, were up 5.8% on Jan 10 after management announced strategic plans to prioritize its drug development efforts in 2024. CCCC seeks to prioritize the advancement ...

C4 Therapeutics, Inc. CCCC or C4T announced that it has entered into an exclusive licensing and collaboration agreement with pharma giant Merck MRK to discover and develop degrader-antibody conjugates ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Calico and C4 Therapeutics (C4T) agreed a 5-year partnership to identify, develop, and commercialize treatments for age-related diseases, including cancer. The collaboration will hinge on C4T’s ...

C4 Therapeutics (CCCC) presented clinical data from the ongoing Phase 1 trial of cemsidomide, an orally bioavailable small molecule degrader of IKZF1/3, at the ASH Annual Meeting. Presentations ...

C4 Therapeutics is sawing off another part of its solely owned pipeline, this time ending work on its clinical-stage BRAF degrader program in order to focus on its IKZF1/3 degrader cemsidomide. The ...

WATERTOWN, Mass.--(BUSINESS WIRE)--C4 Therapeutics (C4T) today announced that Stewart Fisher, Ph.D. has been promoted to Chief Scientific Officer. Since joining C4T as Senior Vice President of ...

WATERTOWN, Mass.--(BUSINESS WIRE)--C4 Therapeutics (C4T) today announced the appointment of Adam Crystal M.D., Ph.D. as Chief Medical Officer. Dr. Crystal will oversee C4T’s activities relating to the ...

Customs solutions provider Customs4Trade NV (C4T) announces a new CEO and two key executive appointments as it strengthens its management to take advantage of accelerating growth in the UK and across ...